Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

News & Events

Researching support needs for dads with children in preterm care

The mental health and wellbeing of new fathers whose children end up in neonatal intensive care is the focus of a new project to be led by The Kids Research Institute Australia researchers, thanks to a $388,000 grant from Healthway. 

News & Events

Stan Perron Charitable Foundation grants boost WA child health research

New funding from the Stan Perron Charitable Foundation will support innovative research projects and programs at The Kids Research Institute Australia with the aim of improving the health and wellbeing of WA children and their families. 

News & Events

Study finds link between family dog ownership and girls’ physical activity

Researchers have found a clear link between the acquisition or loss of a family dog and the level of physical activity undertaken by children in the family, with the impact most noticeable in girls.

News & Events

Welcome boost to medical research and innovation in WA

The Kids Research Institute Australia has welcomed the State Government’s additional investment into the Future Health Research and Innovation Fund (FHRI), which supports key medical research, innovation and commercialisation in Western Australia.

Research

Understanding parent perspectives on engagement with online youth-focused mental health programs

Online youth-focused health programs often include parent modules—that equip parents with skills to assist their child in improving their health—alongside youth-specific content. BRAVE Self-Help, an evidence-based program designed for children and teenagers with early signs of anxiety, is a popular Australian program that includes six parent modules.

Research

Influenza vaccination in Western Australian children: Exploring the health benefits and cost savings of increased vaccine coverage in children

To assess potential benefits and direct healthcare cost savings with expansion of an existing childhood influenza immunisation program, we developed a dynamic transmission model for the state of Western Australia, evaluating increasing coverage in children < 5 years and routinely immunising school-aged children.

Research

Factors Predicting Secondary Respiratory Morbidity Following Early-Life Respiratory Syncytial Virus Infections: Population-Based Cohort Study

The association between early-life respiratory syncytial virus infections and later respiratory morbidity is well established. However, there is limited evidence on factors that influence this risk. We examined sociodemographic and perinatal factors associated with later childhood respiratory morbidity requiring secondary care following exposure to a laboratory-confirmed RSV episode in the first 2 years.

Research

Protocol for the development of a core outcome set for neonatal sepsis (NESCOS)

Neonatal sepsis is a serious public health problem; however, there is substantial heterogeneity in the outcomes measured and reported in research evaluating the effectiveness of the treatments. Therefore, we aim to develop a Core Outcome Set (COS) for studies evaluating the effectiveness of treatments for neonatal sepsis.

Research

Clinical Outcomes with MiniMedTM 780G Advanced Hybrid Closed-Loop Therapy in 2- to 6-Year-Old Children with Type 1 Diabetes

Advanced hybrid closed-loop (AHCL) therapy with the Medtronic MiniMed™ 780G system improves glycemia; however, the clinical outcomes in younger children remain less established. This pilot study aimed to explore the continuous glucose monitoring (CGM) metrics in very young children on AHCL. Children between 2 and 7 years of age and on insulin pump therapy were recruited.

Research

The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings

Sildenafil is used to treat pulmonary hypertension in neonatal intensive care unit (NICU) settings. As multiple intravenous (IV) medications are co-administered in NICU settings, we sought to investigate the physicochemical compatibility of sildenafil with a range of IV drugs.